These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 2142433)
1. Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines. Niedbala MJ; Sartorelli AC Cancer Commun; 1990; 2(5):189-99. PubMed ID: 2142433 [TBL] [Abstract][Full Text] [Related]
2. Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix. Niedbala MJ; Sartorelli AC Cancer Res; 1989 Jun; 49(12):3302-9. PubMed ID: 2497975 [TBL] [Abstract][Full Text] [Related]
3. Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation. Shirasuna K; Saka M; Hayashido Y; Yoshioka H; Sugiura T; Matsuya T Cancer Res; 1993 Jan; 53(1):147-52. PubMed ID: 8380125 [TBL] [Abstract][Full Text] [Related]
4. Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor. Niedbala MJ; Bajetta S; Carbone R; Sartorelli AC Cancer Commun; 1990; 2(9):317-24. PubMed ID: 2169831 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Baker MS; Bleakley P; Woodrow GC; Doe WF Cancer Res; 1990 Aug; 50(15):4676-84. PubMed ID: 2114945 [TBL] [Abstract][Full Text] [Related]
6. Role of glycosidases in human ovarian carcinoma cell mediated degradation of subendothelial extracellular matrix. Niedbala MJ; Madiyalakan R; Matta K; Crickard K; Sharma M; Bernacki RJ Cancer Res; 1987 Sep; 47(17):4634-41. PubMed ID: 2957046 [TBL] [Abstract][Full Text] [Related]
7. Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators. Korner G; Bjornsson TD; Vlodavsky I J Cell Physiol; 1993 Mar; 154(3):456-65. PubMed ID: 8436596 [TBL] [Abstract][Full Text] [Related]
8. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. McGowen R; Biliran H; Sager R; Sheng S Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285 [TBL] [Abstract][Full Text] [Related]
9. Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix. Bar-Ner M; Mayer M; Schirrmacher V; Vlodavsky I J Cell Physiol; 1986 Aug; 128(2):299-306. PubMed ID: 2426287 [TBL] [Abstract][Full Text] [Related]
10. Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition. Norwitz ER; Snegovskikh V; Schatz F; Foyouzi N; Rahman M; Buchwalder L; Lee HJ; Funai EF; Buhimschi CS; Buhimschi IA; Lockwood CJ Am J Obstet Gynecol; 2007 Apr; 196(4):382.e1-8. PubMed ID: 17403427 [TBL] [Abstract][Full Text] [Related]
12. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system. Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451 [TBL] [Abstract][Full Text] [Related]
13. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336 [TBL] [Abstract][Full Text] [Related]
14. Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Koivunen E; Ristimäki A; Itkonen O; Osman S; Vuento M; Stenman UH Cancer Res; 1991 Apr; 51(8):2107-12. PubMed ID: 2009530 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419 [TBL] [Abstract][Full Text] [Related]
16. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase. Vines DJ; Lee SW; Dichek DA; Ellis V J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879 [TBL] [Abstract][Full Text] [Related]
17. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Baricos WH; Cortez SL; el-Dahr SS; Schnaper HW Kidney Int; 1995 Apr; 47(4):1039-47. PubMed ID: 7540230 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of fibrinolytic activity of bovine aortic endothelial cells by ginsenoside Rb2. Liu JW; Wei DZ; Du CB; Zhong JJ Acta Pharmacol Sin; 2003 Feb; 24(2):102-8. PubMed ID: 12546716 [TBL] [Abstract][Full Text] [Related]
19. Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. Lim YT; Sugiura Y; Laug WE; Sun B; Garcia A; DeClerck YA J Cell Physiol; 1996 May; 167(2):333-40. PubMed ID: 8613475 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines. Shiratsuchi T; Ishibashi H; Shirasuna K J Cell Physiol; 2002 Dec; 193(3):340-8. PubMed ID: 12384986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]